Contact us

If you have a question for Quintis, want to know more about our products, or want to discuss commercial orders and collaborations, please call our team on +61 8 6458 4700 or complete our contact form.

See the latest presentation by TFS subsidiary Santalis Pharmaceuticals to the JP Morgan Healthcare Conference held in San Francisco.

Santalis is uniquely situated as a dermatology-focused pharmaceutical company:

  • Proprietary drug substance with sole source supply and significant market protection.

  • Broad biological activity with both disease-specific targets (il-4, il-17, pde4, etc.) and multiple mechanisms of action - applicable to numerous clinical applications.

  • Wide range of high value target clinical indications, many of which have no current RX treatment.

  • Portfolio of late stage clinicals - numerous shots on goal.

  • Diversification into global otc product markets.

Based on comparable valuations for companies at this stage of development, Santalis’ attributes would suggest a valuation in the us$300-$500m range, with significant upside upon progress of its clinical trials through Phase 3 and registration stages.

Previous article Next article